HC Wainwright Analysts Boost Earnings Estimates for NKTR

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for Nektar Therapeutics in a note issued to investors on Tuesday, June 24th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will earn ($2.68) per share for the quarter, up from their previous estimate of ($2.70). HC Wainwright has a "Buy" rating and a $120.00 price objective on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($2.58) EPS, Q4 2025 earnings at ($2.62) EPS, FY2025 earnings at ($11.49) EPS, Q2 2026 earnings at ($3.38) EPS, Q4 2026 earnings at ($3.17) EPS, FY2027 earnings at ($12.17) EPS, FY2028 earnings at ($13.98) EPS and FY2029 earnings at ($7.24) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The firm had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. During the same period in the prior year, the firm earned ($2.70) EPS.

A number of other analysts have also recently weighed in on the stock. BTIG Research upped their price target on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday. Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. Wall Street Zen lowered Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. Oppenheimer upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price on the stock in a report on Friday, March 14th. Finally, William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $76.43.

Nektar Therapeutics Trading Up 1.9%

Shares of NKTR opened at $29.68 on Friday. The firm has a market capitalization of $368.33 million, a P/E ratio of -3.09 and a beta of 0.55. The stock's fifty day simple moving average is $11.19 and its 200 day simple moving average is $12.15. Nektar Therapeutics has a twelve month low of $6.48 and a twelve month high of $37.38.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC increased its holdings in Nektar Therapeutics by 56.3% in the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 9,958 shares during the last quarter. Harvest Investment Services LLC acquired a new stake in Nektar Therapeutics in the 4th quarter worth approximately $27,000. US Asset Management LLC bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth $31,000. Algert Global LLC bought a new stake in Nektar Therapeutics during the first quarter valued at about $33,000. Finally, US Bancorp DE boosted its stake in Nektar Therapeutics by 257.8% during the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 36,085 shares during the period. Institutional investors and hedge funds own 75.88% of the company's stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.